WITHDRAWN: Cell therapies for inflammatory bowel disease

Area of Science:

• Immunology
• Gastroenterology
• Regenerative Medicine

Background:

• Current inflammatory bowel disease (IBD) therapies, including immunosuppressors and biologics, have not reduced the need for intestinal resection in Crohn's disease (CD).
• Unmet needs in IBD treatment include therapy failure and limitations of surgical interventions for extensive or specific lesion locations.
• Cellular therapies, encompassing stem cell therapies and immune cell therapies (dendritic cells, regulatory T cells), are emerging for severe immune-mediated diseases.

Purpose of the Study:

• To explore the potential of cell therapies as novel treatment strategies for refractory inflammatory bowel diseases (IBD), particularly Crohn's disease (CD).
• To review the current landscape and future directions of cell-based interventions for immune-mediated gastrointestinal disorders.

Main Methods:

• Review of experimental and clinical research on cell therapies for immune-mediated diseases.
• Analysis of hematopoietic stem cell transplantation (HSCT) outcomes in therapy-resistant disorders.
• Exploration of tolerance-promoting cell therapies, including mesenchymal stem cells, Tregs, and dendritic cells, in preclinical models.

Main Results:

• Hematopoietic stem cell transplantation (HSCT) has demonstrated significant responses and durable remission in various therapy-resistant immune-mediated disorders.
• HSCT for CD, while promising, remains experimental and is limited to refractory patients due to toxicity.
• Preclinical models suggest that tolerance-promoting cell therapies (mesenchymal stem cells, Tregs, tolerogenic dendritic cells) are effective in autoimmune conditions.

Conclusions:

• Cellular therapies offer a potential paradigm shift in managing refractory IBD, moving beyond immunosuppression towards immune reconstitution and tissue remodeling.
• Tolerance-promoting cell therapies warrant further investigation for IBD, especially in CD, given the proposed role of lost tolerance to gut microbiota.
• Further clinical translation of HSCT and other cell-based strategies is crucial for addressing unmet needs in severe IBD management.